Dott. Simone Parisi

Rheumatologist, enthusiastic photography, astronomy and psychology.

[Dott. Simone Parisi @Sim_Orizon]

🧲🤩 Thrilled to share our new @eular_org #classification criteria for #HaemochromatosisArthropathy! A long-overlooked, iron-driven arthritis finally gets the attention it deserves.
Proud to have contributed to this international effort.
See 👉🏼POS0558
#EULAR2025 #rheumatology

[Dott. Simone Parisi @Sim_Orizon]

At #EULAR2026 we presented our work OP071 on synovial biopsy–driven therapeutic stratification in #PsoriaticArthritis.
Our preliminary data suggest that CD117+ myeloid synovitis may support IL-17/IL-23 axis targeting in selected PsA patients.
#PsA #Rheumatology #PrecisionMedicine

[Dott. Simone Parisi @Sim_Orizon]

🚀4th edition of #Reumasport has just concluded
Challenging the paradigm: patients with rheumatic diseases are not fragile → they are trainable💪
🔥Multidisciplinary approach, exercise as therapy,real-world vision
🚀 #ReumasportStudyGroup is now launched
IG: @reumasport_official

[Dott. Simone Parisi @Sim_Orizon]

🤔Does prior IL-17i exposure affect retention in PsA?
🌍Real-world data from the BIRRA Study Group (868 patients across 24 centres) suggest no major impact.
💡Evidence supporting IL-17i cycling in selected patients.

🔗 https://t.co/7x3M9fvblI

#PsoriaticArthritis #Rheumatology

[Dott. Simone Parisi @Sim_Orizon]

🎙️ New podcast by EMEUNET
With Patrick Kiely, we discuss haemochromatosis arthropathy

🔎 When to suspect it
🦴 Key clinical & radiographic clues
💡 Practical take-home messages

🎧 https://t.co/9HoJkURln0

#Rheumatology #Haemochromatosis #EULAR #MedicalEducation

[Dott. Simone Parisi @Sim_Orizon]

🎉EULAR 2025 Classification Criteria for Haemochromatosis Arthropathy
📘 Ann Rheum Dis 👉 https://t.co/juzyh7FKwr
Proud to be part of this international effort led by Patrick Kiely with amazing colleagues, @EULAR_org & patient partners.
Thanks to @EMEUNET for the opportunity! 💪

[Dott. Simone Parisi @Sim_Orizon]

🧩 New publication “Guselkumab effectiveness in real-world settings: Italian multicentre study”
🔗 https://t.co/S23YQQ1KJa
📌26 Italian rheumatology centers (BIRRA network)
📊 278 PsA patients
#PsoriaticArthritis #Rheumatology #RealWorldEvidence #IL23 #Guselkumab #BIRRAstudy

[Dott. Simone Parisi @Sim_Orizon]

🔎 #Ultrasound as a diagnostic tool in #PMR
New study @Rheumatol_Int ➡️Bilateral subacromial-subdeltoid bursitis > 3 mm can reliably distinguish Polymyalgia Rheumatica from rotator cuff tendinopathy.
📊 Specificity: 96.3%
📊 Sensitivity: 84.2%
👉https://t.co/cAfs24ND9G

[Dott. Simone Parisi @Sim_Orizon]

🧐Granulomatosis with polyangiitis #GPA can present as a diagnostic emergency.A multidisciplinary approach led to timely treatment despite no initial biopsy. Later confirmation: necrotizing vasculitis.Teamwork saves lives.😎
👉🏼https://t.co/mRkgaPcatV 👀
#vasculitis #rheumatology

[Dott. Simone Parisi @Sim_Orizon]

Thanks to @EMEUNET for giving me the opportunity to be part of this Eular Task Force
@k_lauper
@KragstrupTW

[Dott. Simone Parisi @Sim_Orizon]

A landmark moment at #EULAR2025
🏛️ Patrick Kiely presented the EULAR Classification Criteria for Haemochromatosis Arthropathy (HA) — the first-ever criteria for this long-neglected yet disabling condition.
#Haemochromatosis #Arthropathy #EULAR2025 #ClassificationCriteria

[Dott. Simone Parisi @Sim_Orizon]

👏 Kudos to the international task force and patient research partners across 10 countries for this rigorous, data-driven achievement!

[Dott. Simone Parisi @Sim_Orizon]

🧠 Joint pain in C282Y homozygous patients? Think beyond OA. Think HA.
📍 MCP 2–3 involvement, hook osteophytes, early onset, and the iconic “iron fist” are now part of a validated scoring system (specificity 93.3%, sensitivity 71.4%).

[Dott. Simone Parisi @Sim_Orizon]

📢Don’t miss the presentation of the brand-new EULAR Classification Criteria for Haemochromatosis Arthropathy!
🗓️June 14,09:45–10:00
📍Room D1 | Session: EULAR Recommendations II
🎙️Speaker:Patrick Kiely
#EULAR2025 #Rheumatology #Haemochromatosis #Arthropathy #EULARRecommendations

[Dott. Simone Parisi @Sim_Orizon]

🔵Poster POS0334 | #EULAR2025
Colchicine still matters in mucosal #Behçet:
📈Withdrawal led to significant ↑ in oral ulcers at 12 weeks (2.7 vs 0.9; p<0.001)
🔹Higher relapse in women
🔹Also impact on other mucocutaneous lesions.
#BehçetSyndrome #Vasculitis #Colchicine

[Dott. Simone Parisi @Sim_Orizon]

🟣 Poster POS0333 | #EULAR2025
Apremilast shows efficacy in refractory mucosal #Behçet’s syndrome:
🔹93.5% OU response
🔹↓ Ulcer scores
🔹Transcriptomics: downreg of interferon & monocyte pathways
📉Relapse rate still ~43%, but molecular data suggest targeted immune modulation.

[Dott. Simone Parisi @Sim_Orizon]

🧠🫀From EGPA to GCA and ANCA-AAV: exciting insights from poster tours at #EULAR2025!
🧪GC-sparing, PET/CT radiomics,avacopan, OCT biomarkers & MMP-3 for PMR-mimics,vasculitis research is evolving fast.
🔍Science meets clinical relevance!
#Vasculitis #Rheumatology #EGPA #GCA #AAV

[Dott. Simone Parisi @Sim_Orizon]

💪 Finally! At #EULAR2025, a whole session dedicated to the role of sport in RMDs 🙌
From evidence to practice, from inflammation control to pain relief, sport is medicine.
🧠 “A DMARD and a painkiller”? Yes, with data to back it.
#RheumTwitter #ExerciseIsMedicine #RMDs

[Dott. Simone Parisi @Sim_Orizon]

RESET-SSc: CAR-T for SSc
🧪The RESET-SSc trial with rese-cel (anti-CD19 CAR-T) shows:
✅B cell depletion in blood & tissue
✅Skin & lung improvements by Week 24
✅Drug-free response for ≥6 months
✋Nailfold capillaroscopy shows vascular recovery
#CAR_T #SSc #Immunotherapy

[Dott. Simone Parisi @Sim_Orizon]

🌿 An inspiring & high-impact session on #SystemicSclerosis at #EULAR2025!
From vasodilators & PAH therapy to gene modulation and CAR-T for drug-free responses.
Here’s a thread with the highlights 👇
#SSc #Vasculopathy #RheumTwitter

[Dott. Simone Parisi @Sim_Orizon]

Digital ulcers&antifibrotic strategies
🧤Long-term use of selexipag improves SSc-DU outcomes in multicentre data
🧬Tadalafil may modulate skin fibrosis & gene expression in SSc
🧠CRISS & AI trajectories explored in SSc patients on CD19.CAR-T
#SystemicSclerosis